INTRODUCTION
JPET #104950 5 MHC class I-related molecule CD1d. The natural activating ligand for NKT cells has not been identified; alpha-galactosylceramide (α-GalCer, KRN-7000), a synthetic glycolipid, was found to be a potent activator of both mouse and human NKT cells (Kawano et al 1997) .
Glucocerebroside (β-glucosylceramide), a metabolic intermediate in the metabolic pathways of complex glycosphingolipids (Radin and Inokuchi, 1988) , is a naturally occurring glycolipid. The effect of glucocerebroside on NKT cells was examined in recent studies.
CD1d-bound glucocerebroside does not activate NKT cells directly, and may inhibit activation of NKT cells by α -GalCer (Stanic et al, 2003) . In an in vitro study, glucocerebroside was shown to inhibit NKT lymphocyte proliferation in the presence of dendritic cells but not in their absence. In an in vivo study, glucocerebroside prevented development of NKT-mediated concanavalin A-induced hepatitis in a murine model . Clinically, inherited deficiency of glucocerebrosidase, a lysosomal hydrolase, results in Gaucher's disease, characterized by accumulation of glucocerebroside (Elstein et al, 2002) . Patients with Gaucher's disease were recently shown to have an altered number of peripheral blood NKT lymphocytes .
The aim of the present study was to determine the immune modulatory effect of GC on the metabolic and immunological derangements in leptin-deficient ob/ob mice.
Administration of GC induced a marked reduction in hepatic fat content and improved glucose tolerance. This effect was associated with alteration of the intrahepatic lymphocyte subset profile.
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METHODS:
Animals: 8-weeks old male ob/ob mice were purchased from Jackson laboratories (Bar Harbor, ME). Animals were housed in laminar flow hoods in sterilized cages and given irradiated food and sterile acidified water. Animal experiments were carried out in accordance with the guidelines of the Hebrew University-Hadassah Institutional Committee for care and use of laboratory animals and with the committee's approval.
Preparation of glycolipids:
Glucocerebroside was purchased from Avanti Polar Lipids (Alabaster, AL) and dissolved in ethanol. Emulsification in PBS was then performed.
Experimental groups: Four groups of mice were studied. Ob/Ob mice (Groups A and B, N=12 per group) and lean C57BL mice (Groups C and D, N=12/group) were treated by daily injections of GC (1.5 µ g IP, Groups A and C) or PBS with similar ethanol concentration (100µl, Groups B and D) for 8 weeks.
Follow up parameters: Mice were followed by glucose tolerance tests, determination of serum ALT and AST and triglyceride levels, and assessment of liver size and hepatic fat content by magnetic resonance imaging (MRI) and histological examination.
Glucose tolerance test:
Mice underwent a glucose tolerance test on day 60. Glucose was administered orally (1g per kg). Serum glucose measurements were performed on tail-vein blood every fifteen minutes for three hours. Glucose levels were measured by a standard glucometer.
MRI hepatic fat content measurement:
Mice underwent magnetic resonance imaging (MRI) on day 60. Liver size was assessed, and hepatic fat content was measured by a doubleecho chemical shift gradient-echo sequence technique, that provides in-phase and out-ofphase images in a single acquisition for assessment and quantification of liver fat. T1-weighted out-of-phase MR imaging is sensitive for detection of relatively small proportions of tissue fat (Mitchell et al, 1991; Namimoto et al, 2001) . MR images were acquired by a 1.5-T system (Signa LX;GE, Milwaukee, USA). Triglyceride measurement: On day 60, serum triglyceride levels were measured using a spectrophotometer (Cobas DP-25P).
Liver steatohepatitis score: A liver segment from each mouse was fixed in 10%
formaldehyde and embedded in paraffin for histological analysis. Five sections (5 µ m) were stained with hematoxylin/eosin and reviewed by two pathologists in a blinded fashion.
Histological examination and the steatohepatitis grade scoring (NASH score) were performed using the steatohepatitis scoring system (Brunt, 2001 ).
Measurement of serum cytokines: Serum IFNγ, IL10 and IL4 levels were measured by a "sandwich" ELISA method using Genzyme Diagnostic kits (Genzyme Diagnostics, MA, USA), according to manufacturer's instructions.
Isolation of splenic and hepatic lymphocytes for determination of T cell subpopulations:
Mice were sacrificed on day 60 of the experiment. Splenic lymphocytes and NKT cells were isolated and red blood cells removed as previously described (Trop and Ilan, 2002) .
Intrahepatic lymphocytes were isolated as follows: After cutting the inferior vena cava above the diaphragm, the liver was flushed with cold PBS until it become pale, followed by removal of connective tissue and gall bladder. Livers and spleens were crushed through a stainless mesh (size 60, Sigma Chemical Co., St. Louis MO). The cell suspension was placed in a 50ml tube for 3 minutes and washed twice in cold PBS (1,250xrpm for 10 minutes). Cells were re-suspended in PBS, cell suspension was placed through a nylon mesh presoaked in Glucocerebroside treatment also resulted in marked reduction of the hepatic fat content in lean C57BL mice. The SI index was 0.1 in glucocerebroside-treated group C mice compared to 0.18 in untreated group D controls, a reduction of 80% in the intrahepatic fat content. The MFI index decreased from 1.92 to 1.17 in groups D and C, respectively (p<0.05, Fig 1c) .
Effect of glucocerebroside on liver histology:
Histological examination of livers of glucocerebroside-treated ob/ob mice (Group A) compared to control ob/ob mice (Group B) revealed a shift from a mixed micro and macrovesicular steatosis pattern in control mice to a mainly microvesicular pattern in glucocerebroside-treated ob/ob animals. In some animals marked decrease in steatosis was noted ( Figure 3 ). The histological steatohepatitis grading score was 1.95±0.24 compared to 3.16±0.32, for groups A and B, respectively (p<0.005).
Effect of glucocerebroside on serum triglyceride levels:
The serum triglyceride level was significantly lower in glucocerebroside-treated ob/ob mice compared to control ob/ob mice (1.57mmol/l vs. 2.29mmol/l in groups A and B, respectively). Serum triglyceride levels also decreased in lean C57BL mice (1.31mmol/l vs.
1.56mmol/l in glucocerebroside treated vs. untreated animals, respectively).
Effect of glucocerebroside on glucose tolerance:
The glucose tolerance test (GTT) was markedly abnormal in control ob/ob mice (339mg/dl at 1 hour in group B, Figure 4 ). In contrast, glucocerebroside-treated ob/ob mice had an almost normal glucose tolerance curve throughout the three-hour test (glucose level 153mg/dl at 1 hour, p<0.05). No significant effect on fasting plasma glucose levels were noted.
Effect of glucocerebroside on serum liver enzymes:
The serum AST and ALT levels did not differ significantly among the groups on day 60.
Effect of glucocerebroside on body weight: Treatment had no significant effect on body weights, and no statistically significant differences were noted between treated and controls.
Effect of glucocerebroside on intrahepatic and intrasplenic lymphocyte subsets:
FACS analysis of peripheral and intrahepatic lymphocytes revealed a 1.6 fold increase of the peripheral/intrahepatic NKT lymphocyte ratio in glucocerebroside-treated ob/ob mice compared to controls (peripheral/intrahepatic NKT lymphocyte ratio 3.46 vs. 2.13 in group A and B, respectively, P<0.05, Fig 4) ; this ratio increased 3.73 fold in glucocerebroside-treated lean C57BL mice compared to control lean C57BL mice (peripheral/intrahepatic NKT lymphocyte ratio 2.13 vs. 0.57 in groups C and D, respectively, p<0.05, Fig 6) . The intrahepatic CD4+/CD8+ lymphocyte ratio was significantly increased in the GC treated group compared to non treated controls (4.09 vs. 2.18 in groups A and B, respectively, P<0.05). This change was specific to the liver and was not accompanied by a similar change in the peripheral CD4/CD8 ratio (1.53 vs. 1.33 in groups A and B, respectively). Thus, the peripheral to intrahepatic CD4/CD8 ratio increased 1.64 fold in GC treated mice (0.61 vs. 0.37 in groups A and B, respectively, P<0.05), suggesting increased intrahepatic CD8 lymphocyte trapping.
Effect of glucocerebroside on serum cytokine levels:
A 33% decrease of the serum IFNγ level (6.5pg/ml vs. 9.75 pg/ml in groups A and B, respectively) and a 2.6 fold increase of the serum IL10 level (140pg/ml vs. 53pg/ml in groups A and B, respectively, p<0.05) were noted in glucocerebroside-treated ob/ob mice compared to control ob/ob mice. The serum IL4 level did not differ among these groups (Fig 6) .
Glucocerebroside did not affect the serum cytokine levels in lean C57BL mice.
DISCUSSION:
Administration of glucocerebroside alleviated hepatic steatosis and the metabolic syndrome in leptin-deficient ob/ob mice. In treated mice, lower serum triglyceride levels, almost normal glucose tolerance curves and significantly reduced liver size and liver fat content were observed. Glucocerebroside-treated ob/ob mice had an altered immunological profile, including an increased peripheral/intrahepatic NKT lymphocyte ratio and increased CD8+ T lymphocyte trapping.
The concomitant improvement in steatosis and glucose tolerance that was observed in this study following administration of glucocerebroside reinforces the concept of a close interaction between steatosis and the metabolic syndrome in NASH (Koteish and Diehl, 2001 ). Glucocerebroside had an impressive effect on glucose tolerance that was comparable to that observed for currently available drugs, without causing hypoglycemia. The effect of glucocerebroside on body weight differed in animals with steatosis compared to lean controls, suggesting that the mechanism of weight loss was related to a common pathogenic process from which the various derangements characteristic of the metabolic syndrome arise. In contrast, the similar effect of glucocerebroside on the hepatic fat content and serum triglyceride levels in ob/ob and lean C57BL mice, may suggest that the metabolic syndrome is a result of several pathogenic mechanisms, which can be manipulated separately.
NKT lymphocytes, a subpopulation of regulatory lymphocytes, have a role in various infectious, inflammatory, and neoplastic processes (Vincent et al, 2003) . These cells, which are abundant in the liver, are considered to be a link between innate and adaptive immune responses (Bendelac and fearon, 1997) , and were shown to have a role in a number of immune-mediated disorders. In NOD mice, reduced numbers of NKT cells are associated with increased susceptibility to diabetes (Baxter et al, 1997) ; in experimental allergic encephalomyelitis, activation of NKT attenuates the disease (Miyamoto et al, 2001) ; in an animal model of systemic lupus erythematosus, a selective reduction in NKT cells precedes the development of autoimmune phenomena (Takeda and Dennert, 1993) . NKT cells are known to induce hepatic injury in several models, including concanavalin A(Takeda et al,
2000
; Eberl and McDonald, 1998) and salmonella infection (Ishigami et al, 1999 ) -induced liver damage.
Leptin-deficient ob/ob mice feature a dysfunctional immune response, manifested by depletion of hepatic NKT lymphocytes and impaired function of hepatic Kupffer cells (Lee et al, 1999; Loffreda et al, 1998; Li et al, 2002) These alterations may explain the relatively increased sensitivity to LPS-induced hepatotoxicity and resistance to concanavalin A-induced hepatitis and experimental allergic encephalomyelitis observed in these animals (Matarese et al, 2001) . As NKT cells were suggested to have a central role in the pathogenesis of steatosis and steatohepatitis in leptin deficient ob/ob mice (Guebre-Xabier et al, 1999), it can be expected that alteration of their distribution, number, or function may change the course of these disorders. The mechanism by which an effect on NKT lymphocytes results in metabolic consequences remains to be determined. As TNFα receptor knockout ob/ob mice feature improved insulin sensitivity, and administration of anti-diabetic drugs such as metformin and proglitazone, that block TNFα   signaling, results in improved steatosis, it appears that TNFα signaling may be involved in this process (Uysal et al, 1997; Solomon et al, 1997) .
Glucocerebroside was shown to have an immune modulatory effect on NKT cells. In an in vitro study, exposure of NKT cells to glucocerebroside in the presence of dendritic cells inhibited NKT cell proliferation . In the present study, the beneficial effect of GC was associated with a decreased intra-hepatic NKT cell number. Previous studies suggested that a relatively low number of intrahepatic NKT lymphocytes in ob/ob mice may be associated with the pathogenesis of steatosis in these animals. The results of the present study imply that the absolute number of these lymphocytes may be less important than previously suggested, and that a qualitative defect of these cells may be of more significance. The association between a decreased number of NKT lymphocytes and the beneficial clinical effect observed in this study may reflect an inhibitory effect on a subset of "injurious" NKT cells. A similar phenomenon was observed in the concanavalin A-induced hepatitis model .
Leptin deficient ob/ob mice exhibit a unique type of immune profile (Trop and Ilan, 2002) . In the present study, the beneficial effect of GC was associated with a significant decrease in the serum IFNγ level and a significant increase in the serum IL10 level, compatible with further skewing of the cytokine profile in a Th2 direction. This finding suggests that in ob/ob mice, the serum cytokine profile per se, does not explain the characteristic metabolic derangements.
The immune modulatory effect of GC on NKT lymphocytes may be mediated by a direct metabolic effect or by displacement of an activating ligand from the CD1d molecule.
Glucocerebroside-induced apoptosis may be mediated by glucocerebroside itself or by altered levels of other compounds in its metabolic pathway, such as ceramide, which has a wellcharacterized pro-apoptotic effect (Muranaka et al, 2004) . Binding of glycolipids to CD1d is mediated by anchoring of their lipid tail to the hydrophobic pockets of the CD1d antigenbinding groove. Occupation of the CD1d molecule by the ceramide tail of GC, which does not activate NKT lymphocytes, may competitively inhibit binding and presentation of activating ligands, in a similar manner to that recently demonstrated for CD1b, another glycolipidpresenting molecule (Brigl and Brenner, 2004) . It was recently demonstrated that β -galactosylceramide binds to CD1d without activating NKT cells.
We have previously shown that a significant portion of radio labeled glucocerebroside is concentrated in the liver following oral or intraperitoneal administration . The liver is a meeting place for subpopulations of lymphocytes and antigen presenting cells. It has a capacity to preferentially trap activated CD8+ lymphocytes (Mehal et al, 1999) , a process in which NKT cells were shown to participate (Trop and Ilan, 2002) . Inflammatory conditions are characterized by a an increase in the CD4/CD8 T cell ratio (Matsui, 1997; Guebre-Xabier, 2000 ). An opposite shift accompanies liver regeneration following partial hepatectomy (Minagawa, 2000) and alleviation of GVHD. The beneficial effect of GC in this study was associated with an increased peripheral to intrahepatic CD4/CD8 ratio, suggesting increased intrahepatic CD8 lymphocyte trapping. This finding is in line with the correlation between CD8+ T lymphocyte trapping and an anti inflammatory effect that was previously described in several models of immune mediated conditions.
At present, there is no effective pharmacologic therapy for NASH. Attempts have been made to target the underlying metabolic process by administration of a number of pharmacological agents, including vitamin E, metformin, pioglitazone, rosiglitazone, probucol and betaine (Brunt, 2004) , with variable effects on the hepatic fat content and serum aminotransferase levels. Current treatment approaches are directed primarily at achieving control of the metabolic conditions associated with NASH. Very few studies have examined the therapeutic potential of immune modulation in the context of NASH and the metabolic syndrome. While it cannot be ruled out that glucocerebroside has a direct metabolic effect, the immune-modulatory influence observed in this study suggests that its beneficial effect may have been immune mediated. Thus, glucocerebroside may exemplify the relatively new concept of immune-modulation of metabolic processes, which has gained support from increasing experimental evidence that several factors which influence metabolism also have a role in the regulation of immune responses (Matarese and La Cava, 2004) .
Despite the effect of glucocerebroside on hepatic fat content and the metabolic syndrome in ob/ob mice, serum aminotransferase levels did not differ significantly between the study groups. In this study, a therapeutic effect was sought after two months, a relatively short time period. It remains to be determined whether a further reduction in hepatic fat content and an effect on serum aminotransferases would result from a longer treatment regimen. The significance of the transition from a macrovesicular pattern of steatosis to a microvesicular pattern remains unclear. Interestingly, a similar finding was observed with other immune-modulatory interventions that had a beneficial effect in this model (Elinav et al, 2003) . It remains to be determined whether administration of glucocerebroside for a longer period of time would result in a more marked histological response.
In summary, the results of this study suggest that glucocerebroside has a remarkable beneficial effect on hepatic steatosis and the metabolic syndrome in ob/ob mice. This Livers of ob/ob mice that were treated by glucocerebroside (Group A) were significantly smaller than livers of untreated control ob/ob mice (Group B, 1A). There was a significant decrease in the hepatic SI index in the glucocerebroside-treated ob/ob group compared to control ob/ob mice (Groups A and B, Fig 1B) , indicating a significant reduction in the hepatic fat content. As both the liver area and the SI index are correlated with the degree of hepatic fat, their product, MFI (MRI fatty liver index), was calculated to increase the accuracy in detecting a difference between the groups. There was a significant reduction of the MFI in treated (Group A) ob/ob mice compared to untreated ob/ob controls. Glucocerebroside treatment also resulted in marked reduction of the hepatic fat content in lean C57BL mice (1C). The glucose tolerance test (GTT) was markedly abnormal in control ob/ob mice (Group B).
In contrast, glucocerebroside-treated ob/ob mice had an almost normal glucose tolerance curve throughout the three-hour test (Group A). FACS analysis of peripheral and intrahepatic lymphocytes revealed a 1.6 fold increase of the peripheral/intrahepatic NKT lymphocyte ratio (black bars) in glucocerebroside-treated ob/ob mice compared to controls; this ratio increased 3.73 fold in glucocerebroside-treated lean C57BL mice compared to control lean C57BL mice.
The intrahepatic CD4+/CD8+ lymphocyte ratio (open bars) was significantly increased in the GC treated group compared to non treated controls. This change was specific to the liver and was not accompanied by a similar change in the peripheral CD4/CD8 ratio. The peripheral to intrahepatic CD4/CD8 ratio increased 1.64 fold in GC treated mice, suggesting increased intrahepatic CD8 lymphocyte trapping. 
